Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.74 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.58 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.58 |
| ▸ | NEK1 | Q96PY6 | 10/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1450878 | 0.85 | PARP1 (1.00) | PARP1CSNK2A1CSNK2A2CSNK2BNEK1 | |
| SCHEMBL30577701 | 0.85 | PARP1 (1.00) | PARP1CSNK2A1CSNK2A2CSNK2BNEK1 | |
| SCHEMBL20631258 | 0.79 | PARP1 (0.64) | PARP1CSNK2A1CSNK2A2CSNK2BNEK1 | |
| SCHEMBL11933181 | 0.77 | PARP1 (0.65) | PARP1CSNK2A1CSNK2A2CSNK2BNEK1 | |
| SCHEMBL30273142 | 0.76 | PARP1 (0.43) | PARP1KDM4EPARP15TNKS2 | |
| SCHEMBL7027018 | 0.74 | PARP1 (0.48) | PARP1KDM4E | |
| SCHEMBL1451202 | 0.73 | CSNK2A1 (1.00) | PARP1CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL1450877 | 0.73 | PARP1 (0.58) | PARP1CSNK2A1CSNK2A2CSNK2BNEK1 | |
| SCHEMBL1450262 | 0.73 | PARP1 (0.57) | PARP1CSNK2A1CSNK2A2CSNK2BKDM4E | |
| SCHEMBL30273090 | 0.73 | PARP1 (0.57) | PARP1CSNK2A1CSNK2A2CSNK2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4490161-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-119013279-A | Substituted tricyclic compounds as PARP inhibitors and uses thereof | 上海瑛派药业有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2023169226-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | PARP1, PARP2, PARP3 | PARP1 1/4885CSNK2A1 1098/4885CSNK2A2 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.